New approaches to raising the HDL cholesterol level

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Low high-density lipoprotein (HDL) cholesterol is a significant risk factor for atherosclerosis and coronary heart disease.
• Current treatments like fibrates and niacin for low HDL have limitations, necessitating improved therapeutic strategies.
• Elevating HDL cholesterol remains a critical goal in managing cardiovascular risk.

Purpose of the Study:

• To review emerging therapeutic strategies for increasing high-density lipoprotein (HDL) cholesterol levels.
• To focus on novel drug targets with potential for greater efficacy in HDL-C elevation.
• To explore the mechanisms of action for key drug classes under investigation.

Main Methods:

• Review of scientific literature on HDL cholesterol-raising therapies.
• Focus on cholesteryl ester transfer protein (CETP) inhibitors.
• Examination of nuclear orphan receptor agonists targeting ATP-binding cassette transporter 1 (ABC1) expression.

Main Results:

• Cholesteryl ester transfer protein (CETP) inhibitors represent a promising class of drugs for increasing HDL cholesterol.
• Nuclear orphan receptor agonists modulate ATP-binding cassette transporter 1 (ABC1) expression, influencing HDL metabolism.
• These novel approaches offer potential for more effective management of dyslipidemia and cardiovascular risk.

Conclusions:

• Targeting CETP and nuclear orphan receptors offers new avenues for developing superior HDL cholesterol-raising therapies.
• Further research into these mechanisms is crucial for advancing cardiovascular disease prevention.
• Improved HDL cholesterol management through novel drugs could significantly impact patient outcomes.